# Genomics of Drug Sensitivity in Cancer (GDSC): Multi-Omics Analysis of Drug Response

## Abstract

Cancer drug response is highly heterogeneous across tumour types and cellular backgrounds. Understanding the molecular determinants that influence therapeutic sensitivity is essential for advancing precision oncology and improving patient-specific treatment strategies. This report presents a comprehensive exploratory and statistical analysis of the Genomics of Drug Sensitivity in Cancer (GDSC) dataset using genomic, transcriptomic, and epigenomic features. Drug response was evaluated using LN_IC50 values across multiple cancer cell lines.

The study involved data inspection, quality assessment, exploratory data analysis, visualization of drug sensitivity patterns, cancer-specific response profiling, and statistical evaluation of molecular influences on therapeutic response. The findings demonstrate substantial variability in drug sensitivity across cancer cell lines and molecular contexts. Gene expression emerged as the strongest molecular determinant associated with drug response, while copy number alterations and methylation exhibited more selective effects. These results reinforce the importance of integrating multi-omics information in cancer pharmacogenomics and precision medicine research.

---

# Introduction

Cancer is a genetically and molecularly heterogeneous disease characterized by alterations in signaling pathways, transcriptional regulation, and epigenetic modifications (Hanahan and Weinberg, 2011). These molecular variations significantly influence how tumour cells respond to therapeutic agents. While some cancers demonstrate high sensitivity to targeted treatments, others exhibit intrinsic or acquired resistance, making the identification of predictive biomarkers critical for improving treatment outcomes.

Large-scale pharmacogenomic resources such as the Genomics of Drug Sensitivity in Cancer (GDSC) database provide an opportunity to investigate the relationship between molecular features and therapeutic response across hundreds of cancer cell lines and drugs (Yang et al., 2013). The GDSC resource integrates drug sensitivity measurements with genomic and molecular profiling data, enabling researchers to explore mechanisms of sensitivity and resistance (Iorio et al., 2016).

This analysis was conducted to investigate patterns of drug response across cancer cell lines and determine whether genomic, transcriptomic, and epigenomic characteristics influence therapeutic sensitivity. Specifically, the study explored the role of copy number alteration (CNA), gene expression, and methylation status in determining LN_IC50 drug response values.

---

# Objectives

The major objectives of this analysis were:

1. To perform exploratory analysis of the GDSC dataset.
2. To evaluate the distribution and variability of drug sensitivity across cancer cell lines.
3. To identify drugs with the strongest inhibitory effects based on LN_IC50 values.
4. To investigate differences in therapeutic response across cancer types.
5. To assess the influence of genomic, transcriptomic, and epigenomic features on drug sensitivity.
6. To identify statistically significant molecular determinants associated with therapeutic response.

---

# Dataset Description

The analysis utilized the Genomics of Drug Sensitivity in Cancer (GDSC) dataset, which contains pharmacological response measurements across multiple cancer cell lines.

The dataset consisted of approximately 162,103 observations and 19 variables. Key variables included:

| Variable | Description |
|---|---|
| COSMIC_ID | Unique identifier for cancer cell lines |
| DRUG_NAME | Name of therapeutic compound |
| TCGA_DESC | Cancer type classification |
| LN_IC50 | Log-transformed half-maximal inhibitory concentration |
| CNA | Copy number alteration status |
| Gene Expression | Transcriptomic expression category |
| Methylation | Epigenetic methylation status |

Initial inspection revealed:

- Approximately 737 unique cancer cell lines.
- Approximately 246 unique therapeutic compounds.
- Incomplete combinations between drugs and cell lines, indicating that not every drug was tested across all cancer models.
- Presence of duplicated drug-cell line combinations, requiring verification during preprocessing.
- Minimal missing data across major variables.

Column names were standardized by removing whitespace and replacing spaces with underscores to facilitate computational analysis.

---

# Methodology

## Data Preprocessing

Data preprocessing involved importing the dataset using Python libraries including Pandas, NumPy, Matplotlib, and Seaborn. Several preprocessing procedures were performed:

- Column name standardization.
- Data structure inspection using `.info()`, `.describe()`, and `.nunique()`.
- Missing value assessment.
- Duplicate combination checks for drugs and cell lines.
- Variable categorization into continuous and categorical groups.

The LN_IC50 variable served as the primary measure of drug response throughout the analysis.

## Exploratory Data Analysis

Exploratory data analysis (EDA) was conducted to understand the distribution and variability of drug sensitivity patterns.

### Univariate Analysis

Continuous variables were analyzed using:

- Histograms
- Kernel density estimation (KDE) plots
- Box plots
- Summary statistics

Categorical variables were evaluated using frequency distributions and count plots.

### Multivariate Analysis

Relationships between variables were investigated using:

- Scatter plots
- Correlation analyses
- Heatmaps
- Grouped statistical summaries

Drug response patterns were evaluated across cancer types and therapeutic agents.

---

# Drug Sensitivity Analysis

## Most Effective Drugs

Drug effectiveness was assessed by ranking compounds according to median LN_IC50 values across all cancer cell lines. Lower LN_IC50 values indicate stronger inhibitory activity and greater sensitivity to therapeutic compounds (Geeleher et al., 2014).

Several compounds demonstrated particularly low median LN_IC50 values, suggesting high therapeutic potency across diverse cancer models. Standard deviation measurements were also examined to distinguish universally effective compounds from drugs exhibiting selective sensitivity in specific subsets of cell lines.

The ranking analysis provided insight into compounds with broad anti-cancer activity and those with heterogeneous responses.

## Drugs with Highly Variable Responses

Variability analysis identified compounds with large differences in sensitivity across cell lines. Drugs exhibiting high variability may indicate:

- Context-specific therapeutic efficacy
- Molecularly stratified sensitivity
- Potential biomarkers for patient selection
- Resistance-associated cellular pathways

These findings emphasize the biological diversity underlying therapeutic response in cancer systems (Barretina et al., 2012).

---

# Cancer Cell Line Analysis

## Distribution of Drug Sensitivity Across Cancer Types

Drug sensitivity distributions were compared across cancer categories using grouped box plots and median-based ranking approaches.

The analysis demonstrated substantial differences in global LN_IC50 profiles between cancer types. Certain cancer groups consistently exhibited lower median LN_IC50 values, suggesting increased sensitivity to therapeutic agents, while others displayed higher values indicative of broader resistance patterns.

The overall median LN_IC50 served as a reference point for comparing relative sensitivity across tumour classes.

Importantly, cancer-specific patterns highlighted the complexity of therapeutic response. Some cancer types that appeared resistant overall still demonstrated selective sensitivity to particular compounds, supporting the rationale for targeted therapeutic strategies.

## Heatmap Analysis of Drug-Cancer Relationships

Heatmap visualizations were used to examine median LN_IC50 values between cancer types and therapeutic agents.

This analysis revealed:

- Drug-specific sensitivity signatures
- Cancer-specific resistance patterns
- Clusters of therapeutically responsive cancers
- Potential relationships between tumour biology and pharmacological response

The heatmaps provided a systems-level perspective of pharmacogenomic interactions across the dataset.

---

# Genomic, Transcriptomic, and Epigenomic Influence on Drug Response

To investigate whether molecular characteristics influence drug sensitivity in cancer cell lines, a multi-omics analysis was performed using copy number alteration (CNA), gene expression, and methylation status as biological variables, while LN_IC50 was used as the measure of drug response. Independent t-tests were conducted for each drug to compare differences in drug sensitivity between biological groups within each molecular feature category.

The analysis revealed that gene expression demonstrated the strongest and most consistent association with drug response across multiple drugs, consistent with previous pharmacogenomic studies showing that transcriptional states strongly influence therapeutic sensitivity (Geeleher et al., 2014). Several compounds showed statistically significant differences in LN_IC50 values between expression groups, indicating that transcriptional activity may play an important role in determining therapeutic sensitivity. Drugs such as Methotrexate, Doramapimod, RO-3306, NU7441, and 5-Fluorouracil exhibited highly significant gene expression-associated effects, with p-values below 0.05. These findings suggest that variations in gene activity may influence cellular pathways involved in drug uptake, metabolism, signaling, or resistance mechanisms (Subramanian et al., 2017).

In contrast, copy number alteration displayed more selective effects on drug response. While many drugs did not show statistically significant CNA-associated differences, certain compounds including Tanespimycin and Paclitaxel demonstrated significant associations between genomic alteration status and LN_IC50 values. This indicates that genomic structural changes may contribute to sensitivity or resistance for specific therapeutic agents rather than exerting a universal effect across all drugs (Iorio et al., 2016).

Methylation also showed comparatively fewer significant associations with drug sensitivity. However, Methotrexate demonstrated a statistically significant methylation-related effect, suggesting that epigenetic regulation may influence response to selected drugs. Since methylation can alter gene expression through transcriptional silencing, these findings support the role of epigenetic mechanisms in modulating therapeutic outcomes in cancer cells (Hanahan and Weinberg, 2011).

Overall, the results indicate that molecular features contribute differently to drug response patterns across cancer cell lines. Among the three omics layers examined, gene expression emerged as the most influential factor associated with variability in LN_IC50 values. These findings support the concept of precision oncology, where molecular profiling may help predict therapeutic response and guide individualized treatment strategies (Barretina et al., 2012). The analysis further demonstrates the importance of integrating genomic, transcriptomic, and epigenomic information when investigating mechanisms of drug sensitivity and resistance in cancer research.

---

# Statistical Analysis

Independent t-tests were employed to evaluate whether differences in molecular feature groups were associated with statistically significant changes in LN_IC50 values.

For each drug:

- Samples were grouped according to molecular feature status.
- Mean LN_IC50 values were compared between groups.
- P-values below 0.05 were considered statistically significant.

Effect sizes and significance levels were further visualized using volcano plots, enabling simultaneous assessment of biological magnitude and statistical confidence.

This statistical framework facilitated the identification of molecular features that may influence therapeutic response.

---

# Visualization Approaches

Several visualization techniques were used throughout the analysis to improve interpretation and communication of findings.

These included:

| Visualization | Purpose |
|---|---|
| Histograms | Distribution of continuous variables |
| KDE plots | Density estimation of drug response |
| Box plots | Comparison of distributions across groups |
| Scatter plots | Relationships between continuous variables |
| Heatmaps | Drug-cancer interaction patterns |
| Ranked bar plots | Identification of effective drugs |
| Volcano plots | Statistical significance versus effect size |

These visualizations enhanced the interpretability of complex pharmacogenomic relationships.

---

# Biological Interpretation

The findings of this study demonstrate the importance of molecular heterogeneity in determining cancer drug response.

The strong association between gene expression and therapeutic sensitivity suggests that transcriptional states are major drivers of cellular response mechanisms (Geeleher et al., 2014). Altered expression of genes involved in DNA repair, apoptosis, drug metabolism, and signaling pathways may explain differences in sensitivity across cancer models.

The more selective impact of copy number alterations indicates that structural genomic changes contribute to therapeutic response in specific biological contexts. Amplifications or deletions affecting oncogenes and tumour suppressors may influence sensitivity to targeted therapies.

The observed methylation-associated effects support the role of epigenetic regulation in cancer pharmacology. Epigenetic silencing can modify gene activity without altering DNA sequence, potentially affecting pathways involved in drug resistance and tumour progression.

Collectively, these results highlight the value of integrated multi-omics approaches for understanding mechanisms of cancer drug response (Subramanian et al., 2017).

---

# Limitations

Several limitations should be considered when interpreting the findings:

1. Cell line models may not fully recapitulate tumour microenvironment complexity observed in patients.
2. Some drugs were not tested across all cancer cell lines, resulting in incomplete data combinations.
3. Independent t-tests evaluate pairwise differences but may not capture complex nonlinear molecular interactions.
4. Additional clinical and mutational variables could further improve predictive modeling.
5. Association does not necessarily imply causation, and experimental validation would be required to confirm mechanistic relationships.

Despite these limitations, the analysis provides meaningful insights into pharmacogenomic variability and molecular determinants of therapeutic response.

---

# Conclusion

This study performed a comprehensive pharmacogenomic analysis of the GDSC dataset to investigate patterns of cancer drug sensitivity and the influence of molecular features on therapeutic response.

The analysis demonstrated substantial heterogeneity in LN_IC50 values across cancer cell lines, drugs, and tumour types. Several compounds exhibited strong inhibitory activity, while others showed highly variable responses indicative of context-specific sensitivity.

Among the molecular features evaluated, gene expression emerged as the most significant determinant of drug response, showing widespread associations with therapeutic sensitivity across multiple compounds. Copy number alterations and methylation demonstrated more selective but biologically meaningful effects.

These findings reinforce the principles of precision oncology and emphasize the importance of integrating genomic, transcriptomic, and epigenomic information when investigating cancer therapeutics. Multi-omics pharmacogenomic approaches have strong potential for improving biomarker discovery, therapeutic prediction, and individualized treatment strategies in cancer research.

---

# Tools and Libraries Used

The analysis was performed using Python and the following scientific computing libraries:

| Library | Purpose |
|---|---|
| Pandas | Data manipulation and preprocessing |
| NumPy | Numerical computations |
| Matplotlib | Data visualization |
| Seaborn | Statistical graphics |
| SciPy | Statistical testing |

---

# References

1. Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Research*. 2013.
2. Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. *Cell*. 2016.
3. Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. *Genome Biology*. 2014.
4. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*. 2012.
5. Subramanian A, Narayan R, Corsello SM, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. *Cell*. 2017.

